Neonatal respiratory medicine
Exo Biologics focuses on bronchopulmonary dysplasia in extremely preterm newborns, with research centered on respiratory outcomes in the neonatal intensive care setting.
- Bronchopulmonary dysplasia
- Preterm infant lung disease
- Neonatal respiratory support
The sponsor’s activity is directed toward early-life lung injury and the prevention of chronic respiratory complications in vulnerable newborns.
Cell-derived biologic therapies
The clinical program includes mesenchymal-derived extracellular vesicles as an investigational biologic approach, reflecting interest in regenerative medicine and cell-free therapies.
- Extracellular vesicles
- Mesenchymal-derived biologics
- Regenerative neonatal therapy
These studies place emphasis on biologic interventions intended to support lung development and repair in the neonatal period.
Pulmonary protection and disease prevention
Research activity is aimed at reducing the development of grade II-III bronchopulmonary dysplasia, highlighting a preventive focus in pediatric pulmonology.
- Prevention of chronic lung disease
- Neonatal pulmonary protection
- Respiratory morbidity reduction
The sponsor’s therapeutic interest lies in limiting progression to more severe respiratory impairment among high-risk newborns.
Intratracheal neonatal administration
The funded research involves intratracheal administration in newborns, indicating a clinical interest in direct pulmonary delivery for neonatal airway treatment.
- Intratracheal delivery
- Airway-targeted therapy
- Early respiratory intervention
This area connects drug delivery considerations with the management of fragile infant lungs in the earliest stages of life.
